46,900 Shares in Adaptive Biotechnologies Corporation $ADPT Purchased by Jupiter Topco LLC

Jupiter Topco LLC acquired a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 46,900 shares of the company’s stock, valued at approximately $1,006,000.

Several other hedge funds have also recently bought and sold shares of ADPT. BlackRock Inc. bought a new stake in shares of Adaptive Biotechnologies during the 2nd quarter worth approximately $324,735,000. Ameriprise Financial Inc. increased its stake in Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after acquiring an additional 2,731,648 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after purchasing an additional 3,299,635 shares in the last quarter. Westfield Capital Management Co. LP acquired a new position in Adaptive Biotechnologies during the fourth quarter valued at approximately $65,942,000. Finally, Geode Capital Management LLC lifted its stake in Adaptive Biotechnologies by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock worth $57,041,000 after purchasing an additional 110,825 shares during the last quarter. 99.17% of the stock is owned by institutional investors.

Adaptive Biotechnologies Stock Performance

NASDAQ ADPT opened at $24.28 on Friday. The firm’s fifty day moving average price is $23.47 and its two-hundred day moving average price is $17.96. The stock has a market cap of $3.88 billion, a PE ratio of -59.22 and a beta of 2.09. Adaptive Biotechnologies Corporation has a fifty-two week low of $12.00 and a fifty-two week high of $26.87. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The firm had revenue of $71.55 million during the quarter, compared to the consensus estimate of $65.44 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The firm’s revenue was up 21.5% on a year-over-year basis. On average, equities analysts expect that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current fiscal year.

Insider Transactions at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, CEO Chad Robins sold 321,324 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $25.08, for a total value of $8,058,805.92. Following the completion of the transaction, the chief executive officer directly owned 2,180,518 shares in the company, valued at approximately $54,687,391.44. This trade represents a 12.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Harlan Robins sold 492,400 shares of the business’s stock in a transaction dated Tuesday, July 21st. The stock was sold at an average price of $21.89, for a total value of $10,778,636.00. Following the sale, the insider owned 812,058 shares in the company, valued at approximately $17,775,949.62. This trade represents a 37.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 2,011,584 shares of company stock valued at $45,765,999. 5.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

ADPT has been the topic of a number of research analyst reports. Guggenheim raised their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Piper Sandler boosted their price target on Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. TD Cowen raised their price objective on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. BTIG Research lifted their target price on Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Finally, Morgan Stanley boosted their target price on Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $24.42.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.